Company intelligence / Profile preview

OKYO Pharma Limited

Ownership: Public · OKYO
Development stage: Phase 2

Overview

OKYO Pharma's lead drug candidate urcosimod (formerly OK-101) has completed a Phase 2 trial for Dry Eye Disease in Q4 2023 and initiated a Phase 2 trial for Neuropathic Corneal Pain in Q3 2024. The company is the first to receive FDA IND clearance to clinically evaluate a drug specifically for NCP.

Therapeutic areas: OphthalmologyImmunology
Modalities: Small moleculesPeptidesG protein-coupled receptor (GPCR) agonists
Industry: Biotech

Drug pipeline

3 assets

urcosimod

2 more assets in the full pipeline.

Request access →

Financials

Market cap: $58.7M
Total revenue: $0
Enterprise value: $38.1M

Beyond the preview

Go deeper on OKYO Pharma Limited.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on OKYO Pharma Limited.

Explore the full profile